The estimated Net Worth of Lawrence J. Steenvoorden is at least $24.6 millier dollars as of 5 January 2023. Lawrence Steenvoorden owns over 53,571 units of Chembio Diagnostics stock worth over $24,643 and over the last 3 years Lawrence sold CEMI stock worth over $0.
Lawrence has made over 1 trades of the Chembio Diagnostics stock since 2023, according to the Form 4 filled with the SEC. Most recently Lawrence exercised 53,571 units of CEMI stock worth $24,643 on 5 January 2023.
The largest trade Lawrence's ever made was exercising 53,571 units of Chembio Diagnostics stock on 5 January 2023 worth over $24,643. On average, Lawrence trades about 26,786 units every 0 days since 2022. As of 5 January 2023 Lawrence still owns at least 53,571 units of Chembio Diagnostics stock.
You can see the complete history of Lawrence Steenvoorden stock trades at the bottom of the page.
Lawrence's mailing address filed with the SEC is C/O CHEMBIO DIAGNOSTICS, INC., 3661 HORSEBLOCK ROAD, MEDFORD, NY, 11763.
Over the last 20 years, insiders at Chembio Diagnostics have traded over $909,824 worth of Chembio Diagnostics stock and bought 3,754,893 units worth $1,696,058 . The most active insiders traders include Credit Advisors, Llcpercept..., Lawrence A. Siebert et Richard Eberly. On average, Chembio Diagnostics executives and independent directors trade stock every 90 days with the average trade being worth of $36,203. The most recent stock trade was executed by Credit Advisors, Llcpercept... on 21 April 2023, trading 243,448 units of CEMI stock currently worth $109,552.
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
Chembio Diagnostics executives and other stock owners filed with the SEC include: